Detail page

Knowledge Web

Person

Helmut R. Salih (1970-)

Name	Helmut R. Salih
Time	1970- (Date of birth and death)
Place	Deutschland
Variant	Helmut Rainer Salih
Further information	Habil. Fach Innere Medizin
Record type	Person
GND-Identifier	120086565
Record ID	120086565
Involved in show all Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine Targeting CD276 for T cell-based immunotherapy of breast cancer Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro Identification of CD105 (endoglin) as novel risk marker in CLL Platelet-expressed immune checkpoint regulator GITRL in breast cancer SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation Identification of CD318 (CDCP1) as novel prognostic marker in AML An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia The challenges of translation Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study Erratum to: The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG) The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells Expression und Freisetzung immunregulatorischer Oberflächenmoleküle in der Interaktion von Tumor und Immunsystem Einfluß von Heparin auf humane Granulocyten und Monocyten : Anwendung durchflußzytometrischer Verfahren

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Helmut R. Salih (1970-)

Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine

Targeting CD276 for T cell-based immunotherapy of breast cancer

Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody

TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts

In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro

Identification of CD105 (endoglin) as novel risk marker in CLL

Platelet-expressed immune checkpoint regulator GITRL in breast cancer

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation

Identification of CD318 (CDCP1) as novel prognostic marker in AML

An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer

Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia

The challenges of translation

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

The novel deubiquitinase inhibitor b-AP15 induces direct and NK cell-mediated antitumor effects in human mantle cell lymphoma

The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study

Erratum to: The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells

Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)

The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells

Expression und Freisetzung immunregulatorischer Oberflächenmoleküle in der Interaktion von Tumor und Immunsystem

Einfluß von Heparin auf humane Granulocyten und Monocyten : Anwendung durchflußzytometrischer Verfahren